Literature DB >> 6661820

The radioimmunoassay of human placental protein 14 (PP14).

A E Bolton, M G Chapman, R J Stoker, C E Andrew, D Wass, H Bohn.   

Abstract

The development and validation of a radioimmunoassay for the measurement of human placental protein 14 in maternal serum is described. The mean concentration of this protein in serum from 22 normal pregnant women showed a decline during the third trimester from 120 micrograms/l at 27 weeks gestation to 65 micrograms/l at term. Serum samples from 16 patients with intra-uterine growth retardation tended to contain lower concentrations of placental protein 14, these results reaching significance at weeks 36-38 of gestation. Of seven patients with pre-eclampsia from whom two or more blood samples were taken, four showed increases in concentration of this protein as pregnancy proceeded, compared with the normal pattern of decreasing values.

Entities:  

Mesh:

Year:  1983        PMID: 6661820     DOI: 10.1016/0009-8981(83)90287-5

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  4 in total

1.  Placental protein 14 (PP14) inhibits the synthesis of interleukin-2 and the release of soluble interleukin-2 receptors from phytohaemagglutinin-stimulated lymphocytes.

Authors:  A G Pockley; A E Bolton
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

2.  Placental protein 14 (PP14) in late pregnancy.

Authors:  R J Howell; A E Bolton; T Chard
Journal:  Arch Gynecol       Date:  1986

3.  The effect of human placental protein 14 (PP14) on the production of interleukin-1 from mitogenically stimulated mononuclear cell cultures.

Authors:  A G Pockley; A E Bolton
Journal:  Immunology       Date:  1990-02       Impact factor: 7.397

4.  Characterisation of the differential expression of marker antigens by normal and malignant endometrial epithelium.

Authors:  E Chatzaki; C J Gallagher; R K Iles; T E Ind; A M Nouri; C M Bax; J G Grudzinskas
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.